Where can I find news about MIRM?

The latest press releases, SEC filings, and earnings call transcripts for Mirum Pharmaceuticals, Inc. (MIRM) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are MIRM's SEC filings?

Mirum Pharmaceuticals, Inc. (MIRM)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was MIRM's last earnings call?

The most recent earnings call transcript for Mirum Pharmaceuticals, Inc. (MIRM) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

MIRM

Mirum Pharmaceuticals, Inc.

NASDAQ·Biotechnology · Healthcare

$117.05$0.43+0.37%

Pre-market·$117.04−0.01%

Market cap$5.88B·Market closed·Jul 21 8:00 PM UTC

Press Releases

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
businesswire.comJul 13, 2026 · 4:01 PM
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.
seekingalpha.comJul 4, 2026 · 3:48 AM
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.comJun 29, 2026 · 11:56 AM
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
etftrends.comJun 25, 2026 · 11:31 AM
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
zacks.comJun 17, 2026 · 7:51 AM
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
zacks.comJun 16, 2026 · 4:56 AM
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
zacks.comJun 15, 2026 · 11:45 AM
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
gurufocus.comJun 14, 2026 · 5:00 PM

SEC Filings

8-K
Jun 18, 2026View on SEC
8-K
May 18, 2026View on SEC
10-Q
May 6, 2026View on SEC
8-K
May 6, 2026View on SEC
8-K
May 4, 2026View on SEC
SC 13G/A
Apr 27, 2026View on SEC

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for MIRM and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About MIRM

Where can I find news about MIRM?: The latest press releases, SEC filings, and earnings call transcripts for Mirum Pharmaceuticals, Inc. (MIRM) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are MIRM's SEC filings?: Mirum Pharmaceuticals, Inc. (MIRM)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was MIRM's last earnings call?: The most recent earnings call transcript for Mirum Pharmaceuticals, Inc. (MIRM) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Mirum Pharmaceuticals, Inc.

Frequently Asked Questions About MIRM

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

Biotech ETF Index Surges 10% After Rebalance

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Frequently Asked Questions About MIRM

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

Biotech ETF Index Surges 10% After Rebalance

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva